Stroke, Ischemic
Conditions
Brief summary
This is a single centre、single arm、open-label，to investigate the safety and efficacy of EPC transplantation in the brain
Detailed description
The purpose of this study is to evaluate the efficacy and safety of transplantation EPCs intervent subjests with cerebral hemorrhagic stroke.
Interventions
BIOLOGICALEPC treatment group
Brain injection EPC
Sponsors
Allife Medical Science and Technology Co., Ltd.
Study design
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects ≥ 18 and ≤ 80 years of age 2. Subjects was confirmed cerebral hemorrhagic stroke, included at least one of risk factors(Hypertension, diabetes, coronary heart disease, high blood lipid), and Satisfied with one of the following conditions: A. Significant stenosis (\> 50%) of the intracranial and extracranial arteries or their branches due to atherosclerosis, or clinical or imaging manifestations of vascular blockage B. Head imaging (CT or MRI) : cerebral hemispheric infarct lesion diameter of \> 1.5cm; Or there were more than 2 discontinuous lesions in the blood supply area of the same intracranial external artery. C. Auxiliary examination: color ultrasonography, CTA, MRA or DSA of the blood vessels in the neck confirmed that the intracranial or extracranial stenosis was greater than or equal to 50%； 3. Serum creatinine ≤ 1.5 mg/dl ； Serum ALT/AST）≤2.5×ULN；ALB≥25g/L； 4. Serum creatinine≤ 176.8umol/L（2.0 mg/dl）； 5. Prothrombin time（PT）≤15s，International standardization rates（INR）\<1.7； 6. The glucose should be control between 2.8\ 22.2mmol/L（50\ 400mg/dl）； 7. Adult patients were willing to use reliable contraceptives (such as condoms) and not to donate sperm throughout the study period and within three months of discharge 8. Subjects and the guardians able to undergo post-physical therapy/rehabilitation
Exclusion criteria
1. Non-atherogenic cerebral infarction: cardiogenic embolization, small artery occlusion type IS, other exact etiology IS, and unknown etiology IS 2. Combined with cerebral hemorrhage or previous intracranial external blood history, arteriovenous malformation and aneurysm history, or prone to hemorrhage (platelet count below 100 x 109/L) 3. The vital signs of subjects are not stable 4. Subjects with Class III/IV cardiovascular disability according to the New York Heart Association Classification 5. At rest systolic pressure of 170mmHg or diastolic pressure of 105mmHg, or other indications of uncontrolled hypertension 6. Subjects have one kinds of tumors within 5 years 7. The subject was suffering from neurological or mental illness 8. Subjects had congenital or acquired immune deficiencies, active tuberculosis and other active infections (e.g., pulmonary infection, urinary tract infection, skin infection) 9. alcoholics 10. Receipt of any investigational drug or device within 3 month 11. Active hepatitis B (HBV DNA\>1000copy/mL), hepatitis C or HIV infection 12. Subjects who have other conditions that were not appropriate for the group determined by the researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Treatment Emergent AE | 1 year | Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment |
Outcome results
None listed